Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD44 shRNA
- Development stage
- Preclinical
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral, Intraperitoneal, Intravenous, Intradermal, Topical, Transdermal, Percutaneous, Intratumoral
01
Overview
CD44 shRNA is a gene-silencing tool that utilizes short hairpin RNA (shRNA) to target and reduce the expression of CD44, a cell-surface glycoprotein associated with cancer stem cell (CSC) properties and therapy resistance. In preclinical models of hepatocellular carcinoma (HCC), CD44 shRNA has been shown to disrupt the CD44/mTOR signaling axis, which in turn suppresses autophagy and CSC-mediated survival. This knockdown enhances the sensitivity of HCC cells to radiation therapy (radiosensitivity) and increases radiation-induced apoptosis, suggesting its potential as a therapeutic strategy to overcome radioresistance in advanced or refractory liver cancer.
- Other names
- shRNA-mediated CD44 knockdown
02
Targets
CD44 (CD44 antigen)
Beyond the preview
Go deeper on CD44 shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD44 shRNA.